pyrroles has been researched along with Recrudescence in 117 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.85) | 18.7374 |
| 1990's | 4 (3.42) | 18.2507 |
| 2000's | 40 (34.19) | 29.6817 |
| 2010's | 67 (57.26) | 24.3611 |
| 2020's | 5 (4.27) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Cui, B; Hao, Q; Huang, W; Liu, F; Wang, J; Xue, S; Zhang, Y | 1 |
| Dubinsky, MC; Irving, PM; Leung, Y | 1 |
| Cai, Z; Cui, S; Dai, S; Dong, Y; Lin, N; Liu, P; Shi, J; Tong, B; Wu, X | 1 |
| Deguchi, H; Higuchi, K; Igarashi, A; Takeuchi, T; Uda, A; Yokoya, Y | 1 |
| Fujiwara, M; Ishikawa, Y; Kasuya, T; Kita, Y | 1 |
| Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T | 1 |
| Ashida, K; Funao, N; Kawai, T; Mizokami, Y; Nishimura, A; Oda, K; Soen, S; Sugano, K | 1 |
| Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K | 1 |
| Contreras-Yáñez, I; Ortiz-Haro, AB; Pascual-Ramos, V; Pérez-Román, DI; Ruiz-Medrano, E | 1 |
| Aoyama, T; Cho, H; Hayashi, T; Kano, K; Maezawa, Y; Masuda, M; Ogata, T; Oshima, T; Rino, Y; Sato, T; Yamada, T; Yoshikawa, T; Yukawa, N | 1 |
| Hanada, Y; Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kaise, M; Kawami, N; Koizumi, E; Takenouchi, N; Umezawa, M | 1 |
| Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E | 2 |
| Hayashi, Y; Kawarai Lefor, A; Kobayashi, Y; Miura, Y; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Bastian, Y; Castañeda-Delgado, JE; Castañeda-Sánchez, JJ; Castillo-Ortiz, JD; Enciso-Moreno, JA; Fernández-Ruiz, JC; González-Amaro, R; Monsivais-Urenda, AE; Ochoa-González, F; Ramos-Remus, C; Romo-García, MF; Sánchez-Corona, J | 1 |
| Abudu, M; Gordon, SC; Ko, JM; Rosmarin, D; Zancanaro, P | 1 |
| Almutairi, N; Hussain, NH; Nour, TM | 1 |
| Deng, W; Sun, L; Wu, Q; Zhang, Z | 1 |
| Goto, O; Hanada, Y; Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kaise, M; Kawami, N; Takenouchi, N; Tanabe, T | 1 |
| Hinoue, Y; Kamiyamamoto, S; Mizuno, H; Nishino, M; Yamada, K | 1 |
| Brodowski, K; Jaworski, K; Kosior, DA; Krzykwa, A; Opolski, G; Zylińska, E | 1 |
| Boers-Sonderen, MJ; Hoentjen, F; Jacobs, JF; Mulder, SF; Nagtegaal, ID; van Herpen, CM; Wanten, GJ | 1 |
| Mateos, MV; Ocio, EM; San Miguel, JF | 1 |
| Akahoshi, S; Inoue, K; Kiyota, Y; Kiyozumi, Y; Motooka, Y; Yamaguchi, R; Yoshida, Y | 1 |
| Chatterjee, P; Kumar, R; Sikka, K | 1 |
| Albers, GW; Tai, WA | 1 |
| Baker, DA; Lim, Y; Makky, K; Mantsch, JR; McReynolds, JR; Thao, M; Vranjkovic, O | 1 |
| Liang, H | 1 |
| Li, Y; Qi, X; Yang, Q | 1 |
| Cozzi, R; Lo Schiavo, A; Puca, RV; Romano, F | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kuroda, Y; Kusama, H; Matsushita, K; Morimoto, Y; Nakahira, S; Nakatsuka, S; Nitta, K; Ohmura, Y; Ohzono, K; Okishiro, M; Sakisaka, H; Sato, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Abdel-Rahman, I; Murphy, C | 1 |
| Bashir, A; Bollag, G; Burton, EA; Carias, H; Damon, LE; Habets, G; Hsu, HH; Ibrahim, PN; Kasarskis, A; Lasater, EA; Le, MH; Lin, KC; Massi, E; Matusow, B; Pendleton, M; Perl, A; Powell, B; Sebra, R; Shah, NP; Shellooe, R; Smith, CC; Spevak, W; Tsang, G; West, BL; Zhang, C; Zhang, J; Zhang, Y | 1 |
| Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L | 1 |
| Carreño-Rojo, A; Chica-Marchal, A; Huertas, AJ; Mérida-Fernández, C; Ramírez-Hernández, M | 1 |
| Kamata, S; Yoshinaga, A | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Bekaii-Saab, T; Blazer, M; Chen, JL; Clark, DJ; El-Dika, S; Knopp, MV; Liu, J; Mikhail, S; Neal, A; Rock, J; Tahiri, S; Timmers, C; Walker, J; Wei, L; Wu, C; Yang, X | 1 |
| Kayser, G; Klement, GL; Rössler, J; Saueressig, U; von Winterfeld, M | 1 |
| Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R | 1 |
| Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM | 1 |
| Cannell, PK; Harrison, SJ; Mainwaring, P; Millward, MJ; Padrik, P; Price, T; Reich, SD; Spencer, A; Trikha, M; Underhill, CR | 1 |
| Alpert, A; Awisat, A; Boulman, N; Ginsberg, S; Kaly, L; Rimar, D; Rosner, I; Rozenbaum, M; Shen-Orr, SS; Slobodin, G; Starosvetsky, E; Zilber, K | 1 |
| Munakata, S; Shiba, M; Takayama, H; Takeda, K; Wang, C | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Császár, A | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Zivin, J | 1 |
| Hanhart, J; Koskas, P; Le Mer, Y; Obadia, M; Paques, M; Sahel, JA | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM | 1 |
| Alt, M; Andrès, E | 1 |
| Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC | 1 |
| Bao, W; Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG | 1 |
| Amraoui, S; Boulon, C; Conri, C; Constans, J; Solanilla, A; Viguier, JB | 1 |
| Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L | 1 |
| Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY | 1 |
| Colivicchi, F; Genovesi Ebert, A; Melina, G; Mocini, D; Santini, M; Strano, S; Tubaro, M; Uguccioni, M | 1 |
| Dougu, N; Nukui, T; Taguchi, Y; Takashima, S; Tanaka, K; Toyoda, S | 1 |
| Dermitzakis, I; Drakoulis, C; Gialernios, K; Gialernios, T; Gika, E; Iliopoulos, N; Katsadorou, E; Kougialis, S; Kroustalis, A; Mpilinis, H; Nikolaou, S; Polydorou, A; Polydorou, V; Skopelitis, E; Zervou, A | 1 |
| Cannon, CP; Khera, AV; Qin, J; Rader, DJ; Wolfe, ML | 1 |
| Biagi, JJ; Chalchal, HI; Eisenhauer, EA; Ellard, SL; Grimshaw, R; Hirte, H; Ivy, SP; Lee, U; Oza, AM; Sederias, J | 1 |
| Cagli, B; Intagliata, S; Onetti Muda, A; Perrone, G; Persichetti, P; Santini, D; Segreto, F; Tonini, G | 1 |
| Chaskis, C; De Greve, J; Duerinck, J; Dujardin, M; Everaert, H; Lv, S; Michotte, A; Neyns, B; Nupponen, N; Sadones, J; Tynninen, O | 1 |
| Agresta, S; Antonia, S; Calitri, CE; Chiappori, A; D'Amato, G; Dean, M; Garrett, C; Han, G; Mahmood, ST; Schell, MJ; Vigil, CE; Zhao, X | 1 |
| Almroth, H; Andersson, J; Boman, K; Englund, A; Höglund, N; Jensen, S; Rosenqvist, M; Tornvall, P | 1 |
| Djoussé, L; Gaziano, JM; Rahilly-Tierney, C; Sesso, HD | 1 |
| Nishida, T; Omori, T; Ueshima, S | 1 |
| Sillence, D; Tchan, M | 1 |
| Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L | 1 |
| Chedgy, F; Howlett, DC; Inglis, C | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| DE Grève, J; DE Witte, O; DU Four, S; Huylebrouck, M; LE Mercier, M; Lv, S; Michotte, A; Neyns, B; Quartier, E; Sadones, J; Salmon, I; Teugels, E | 1 |
| Chika, N; Kakimoto, M; Kikuchi, A; Koshiishi, H; Nishida, K; Okamura, T; Tokita, H; Yoshimura, T | 1 |
| Copeland, A; Fanale, M; Fayad, LE; Hagemeister, F; Oki, Y; Romaguera, J; Younes, A | 1 |
| Almroth, H; Andersson, J; Boman, K; Englund, A; Höglund, N; Jensen, SM; Rosenqvist, M; Tornvall, P | 1 |
| Carlson, SJ; Fallon, EM; Mitchell, PD; Nedder, AP; Nehra, D; Potemkin, AK; Puder, M; Rueda, BR | 1 |
| Hiramatsu, Y; Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T | 1 |
| Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL | 1 |
| Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Minato, H; Morioka, E; Nakano, Y; Nakata, S; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Takamura, H; Tomita, Y; Ueda, N | 1 |
| Benda, B; Blanco, R; Bradley, J; Burmester, GR; Charles-Schoeman, C; Gruben, D; Koncz, T; Krishnaswami, S; Mebus, C; Soma, K; Wallenstein, G; Wollenhaupt, J; Zerbini, C; Zwillich, SH | 1 |
| Ammirati, F; Colivicchi, F; Guido, V; Montefoschi, N; Santini, M; Tubaro, M; Varveri, A | 1 |
| Aktas, O; Brocke, S; Dorr, J; Endres, M; Nitsch, R; Prozorovski, T; Sallach, S; Seeger, B; Smorodchenko, A; Waiczies, S; Zipp, F | 1 |
| Baumgartner, RW; Georgiadis, D | 1 |
| Correia, LC; D'Oliveira, A; Esteves, JP; Magalhães, LP; Passos, LC; Rocha, MS; Santana, O; Spósito, AC | 1 |
| Briesewitz, R; Bruner, RJ; Caligiuri, MA; Griffin, JH; Leung, J | 1 |
| Berdel, WE; Brega, NM; Cavalli, F; Duhrsen, U; Fiedler, W; Flasshove, M; Hossfeld, DK; Jacobs, M; Jung, W; Kuse, R; Loges, S; Mesters, R; O'Farrell, AM; Ottmann, OG; Scigalla, P; Serve, H; Staib, P; Thomalla, J; Tinnefeld, H | 1 |
| Cherrington, JM; Lee, LB; London, CA; Pryer, NK; Sukbuntherng, J; Yu, X; Zadovaskaya, R | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Dolan, JG; Nautiyal, A; Singh, S | 1 |
| Bernsen, HJ; Bussink, J; Peeters, W; Schuuring, J; van Der Kogel, AJ | 1 |
| Casciano, R; Gómez-Gerique, JA; Rejas, J; Stern, L | 1 |
| Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Waters, D; Zeiher, A | 1 |
| Lavoie, S; Lipson, J; Zimmerman, D | 1 |
| Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Clearfield, M | 1 |
| Altinbas, A; Aslan, SM; Dogan, A; Kucuktepe, Z; Ozaydin, M; Ozturk, M; Varol, E | 1 |
| Cía, M; Martínez, M; Otermin, I; Pereda, A; Rivero, M | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Heering, NJ | 1 |
| Antel, J; Arnold, DL; Bar-Or, A; Bodner, CA; Campagnolo, D; Garren, H; Gianettoni, J; Jalili, F; Kachuck, N; Lapierre, Y; Niino, M; Oger, J; Price, M; Rhodes, S; Robinson, WH; Shi, FD; Steinman, L; Utz, PJ; Valone, F; Vollmer, T; Weiner, L | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Karam, JG; Loney-Hutchinson, L; McFarlane, SI | 1 |
| Aktas, O; Bellmann-Strobl, J; Dörr, J; Haertle, M; Paul, F; Volk, HD; Waiczies, H; Waiczies, S; Wernecke, KD; Wuerfel, J; Zipp, F | 1 |
| Ballantyne, CM; Davidson, MH; Hanefeld, M; Johnson, JL; Mohler, ER; Ruilope, LM; Zalewski, A | 1 |
| Chujo, M; Hori, M; Inoue, M; Kamada, T; Kitakaze, M; Komamura, K; Minamino, T; Mori, H; Node, K; Shinozaki, Y | 1 |
| Black, D; Chaitman, BR; Ezekowitz, MD; Ganz, P; Kane, JP; Oliver, MF; Olsson, AG; Pressler, ML; Schwartz, GG; Texter, M; Waters, D | 1 |
| Baim, DS; Carrozza, JP; Cohen, DJ | 1 |
| Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM | 1 |
| Hoekman, K; Jorna, AS; Pinedo, HM; Smit, EF; Verheul, HM | 1 |
| Cheson, BD; Conley, BA; Gore-Langton, RE | 1 |
| Harding, S; Juzytsch, W; Lê, AD; Shaham, Y; Shalev, U; Watchus, J | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Chaitman, BR; Ezekowitz, MD; Ganz, P; Leslie, S; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, D; Zeiher, A | 1 |
| Purkiss, P; Wajner, M; Wannmacher, CM | 1 |
| Tietjen, DP | 1 |
8 review(s) available for pyrroles and Recrudescence
| Article | Year |
|---|---|
Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Recurrence | 2022 |
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Asia, Eastern; Drug Therapy, Combination; Herpes Zoster; Herpesvirus 3, Human; Humans; Mycobacterium tuberculosis; Piperidines; Prevalence; Pyrimidines; Pyrroles; Recurrence; Risk; Tuberculosis; Virus Activation | 2019 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrroles; Recurrence; Thalidomide; Treatment Outcome | 2013 |
The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials.
Topics: Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Odds Ratio; Primary Prevention; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Secondary Prevention; Treatment Outcome | 2014 |
Personalized Therapy for Generalized Lymphatic Anomaly/Gorham-Stout Disease With a Combination of Sunitinib and Taxol.
Topics: Administration, Metronomic; Adolescent; Child; Chronic Pain; Combined Modality Therapy; Dietary Fats; Drug Synergism; Drug Therapy, Combination; Fatal Outcome; Humans; Indoles; Lymphatic Abnormalities; Male; Osteolysis, Essential; Paclitaxel; Pelvic Bones; Pleural Effusion; Precision Medicine; Pyrroles; Radiography; Recurrence; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Sunitinib; Triglycerides | 2015 |
[Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Tongue Neoplasms | 2016 |
[Important aim of statin therapy: ischemic cardiovascular event (stroke)].
Topics: Acute Disease; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Ischemia; Pyrroles; Recurrence; Stroke | 2008 |
[Secondary prevention after ischemic stroke].
Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Carotid Stenosis; Endarterectomy, Carotid; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Smoking Prevention; Stents; Stroke; Vertebral Artery Dissection | 2003 |
40 trial(s) available for pyrroles and Recrudescence
| Article | Year |
|---|---|
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence Trials as Topic; Female; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Pyrroles; Recurrence; Secondary Prevention; Single-Blind Method; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Japan; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Pyrroles; Recurrence; Secondary Prevention; Sulfonamides; Treatment Outcome | 2018 |
Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis.
Topics: Aged; Esophagitis, Peptic; Fasting; Female; Gastrins; Humans; Japan; Maintenance Chemotherapy; Male; Middle Aged; Patient Satisfaction; Practice Guidelines as Topic; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Recurrence; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2018 |
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gastric Mucosa; Gastroesophageal Reflux; Heartburn; Humans; Incidence; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Treatment Outcome | 2018 |
Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; MicroRNAs; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Recurrence | 2018 |
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Topics: Administration, Oral; Adolescent; Adult; Alopecia; Alopecia Areata; Female; Hair; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; Time Factors; Young Adult | 2019 |
Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
Topics: Aged; Drug Administration Schedule; Esophageal Mucosa; Esophagitis, Peptic; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2020 |
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine | 2015 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.
Topics: Adult; Aged; Angiogenesis Inhibitors; Complement Factor B; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Recurrence; Sunitinib; Transcriptome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C | 2015 |
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Topics: Adult; Aged; Cytochrome P-450 CYP2C19; Double-Blind Method; Esophagitis; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Wound Healing | 2016 |
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lactones; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrroles; Recurrence; Thalidomide | 2016 |
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Lactones; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Proteasome Inhibitors; Pyrroles; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2016 |
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Female; Fibrin Fibrinogen Degradation Products; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Recurrence; Risk; Tissue Plasminogen Activator | 2009 |
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesylates; Middle Aged; Patient Selection; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Topotecan | 2010 |
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Circulation; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Korea; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Recurrence; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Italy; Male; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2010 |
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Factors; Triglycerides | 2010 |
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-125 Antigen; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrroles; Recurrence; Sunitinib; Survival Analysis | 2011 |
Phase II study of sunitinib malate in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Cerebrovascular Circulation; Disease Progression; Female; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrroles; Pyrrolidinones; Receptors, Platelet-Derived Growth Factor; Recurrence; Regional Blood Flow; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
Topics: Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histiocytoma, Malignant Fibrous; Humans; Indoles; Leiomyosarcoma; Liposarcoma; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Recurrence; Retreatment; Sarcoma; Sunitinib; Survival Rate | 2011 |
Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Electric Countershock; Female; Fibrinolysis; Heptanoic Acids; Humans; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Recurrence; Tissue Plasminogen Activator | 2011 |
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Indoles; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Treatment Outcome | 2012 |
The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Double-Blind Method; Electric Countershock; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Recurrence; Treatment Outcome | 2013 |
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Pain Measurement; Piperidines; Pyrimidines; Pyrroles; Recurrence; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pyrroles; Recurrence; Survival Rate | 2002 |
Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2003 |
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Cell Separation; Enzyme Inhibitors; Female; Flow Cytometry; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Microcirculation; Middle Aged; Mutation; Polymerase Chain Reaction; Pyrroles; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2003 |
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Topics: Aged; Angina Pectoris; Angina, Unstable; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomarkers; CD40 Ligand; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pyrroles; Recurrence; Risk; Solubility; Treatment Outcome | 2004 |
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Myocardial Infarction; Myocardial Ischemia; Prognosis; Proportional Hazards Models; Pyrroles; Recurrence | 2005 |
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Topics: Acute Disease; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Metabolic Syndrome; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Pyrroles; Recurrence; Risk Factors; Treatment Outcome | 2005 |
Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Body Mass Index; C-Reactive Protein; Electric Countershock; Female; Heptanoic Acids; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Recurrence; Risk Factors; Treatment Outcome | 2006 |
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Topics: Adult; Atorvastatin; Disability Evaluation; Double-Blind Method; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immune Tolerance; Immunization; Injections, Intramuscular; Lymphocyte Count; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Oligonucleotide Array Sequence Analysis; Plasmids; Pyrroles; Recurrence; T-Lymphocytes; Vaccines, DNA | 2007 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Atorvastatin; Gadolinium; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Interleukins; Magnetic Resonance Imaging; Models, Biological; Multiple Sclerosis, Relapsing-Remitting; Multivariate Analysis; Pyrroles; Recurrence; Treatment Outcome | 2008 |
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Benzaldehydes; Biomarkers; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; Male; Middle Aged; Oximes; Prognosis; Pyrroles; Recurrence; Risk Factors | 2008 |
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Recurrence; Survival Analysis | 2001 |
69 other study(ies) available for pyrroles and Recrudescence
| Article | Year |
|---|---|
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazoles; Pyrroles; Recurrence; Retrospective Studies; Triazines | 2022 |
Constructing Hypoxia-Tolerant and Host Tumor-Enriched Aggregation-Induced Emission Photosensitizer for Suppressing Malignant Tumors Relapse and Metastasis.
Topics: Humans; Hypoxia; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles; Reactive Oxygen Species; Recurrence | 2022 |
Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Topics: Computer Simulation; Cost-Benefit Analysis; Esomeprazole; Gastroesophageal Reflux; Humans; Japan; Markov Chains; Proton Pump Inhibitors; Pyrroles; Quality-Adjusted Life Years; Rabeprazole; Recurrence; Sulfonamides; Time Factors; Treatment Outcome | 2019 |
Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
Topics: Autoantibodies; Dermatomyositis; Female; Humans; Interferon-Induced Helicase, IFIH1; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence | 2020 |
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib | 2017 |
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Ethics, Research; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Remission Induction; Research Design; Research Subjects; Time Factors; Treatment Outcome; Vulnerable Populations | 2018 |
[A Long-Term Survivor Who Are Responding to Sunitinib Treatment for Recurrent Imatinib-Resistant Gastrointestinal Stromal Tumor(GIST)of the Stomach].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Pyrroles; Recurrence; Stomach Neoplasms; Sunitinib; Time Factors | 2017 |
Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Topics: Aged; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proton Pump Inhibitors; Pyrroles; Quality of Life; Recurrence; Retrospective Studies; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires; Wound Healing | 2018 |
Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
Topics: Adult; Alopecia Areata; Female; Humans; Janus Kinases; Middle Aged; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Recurrence; Withholding Treatment | 2019 |
Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
Topics: Aged; Drug Resistance; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastric Mucosa; Gastrins; Humans; Maintenance Chemotherapy; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Symptom Assessment; Time Factors | 2019 |
[Role of inflammation in etiology of atrial fibrillation--is lone arrhythmia really alone].
Topics: Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Recurrence | 2012 |
Severe exacerbation of Crohn's disease during sunitinib treatment.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Crohn Disease; Disease Progression; Fatal Outcome; Glucocorticoids; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prednisone; Pyrroles; Recurrence; Risk Factors; Severity of Illness Index; Sunitinib; Treatment Outcome | 2014 |
[A case of imatinib-resistant gastrointestinal stromal tumor treated with low-dose sunitinib].
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Salvage Therapy; Sunitinib | 2013 |
Nephrogenic epistaxis.
Topics: Adult; Carcinoma, Renal Cell; Chemoradiotherapy; Diagnosis, Differential; Epistaxis; Humans; Indoles; Kidney Diseases; Male; Neoplasm Metastasis; Nose; Nose Neoplasms; Positron-Emission Tomography; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2014 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Life Style; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Risk Factors; Secondary Prevention; Stroke; Ticlopidine | 2014 |
Beta-2 adrenergic receptors mediate stress-evoked reinstatement of cocaine-induced conditioned place preference and increases in CRF mRNA in the bed nucleus of the stria terminalis in mice.
Topics: Adrenergic beta-Agonists; Animals; Behavior, Addictive; Clenbuterol; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Corticotropin-Releasing Hormone; Dopamine Uptake Inhibitors; Extinction, Psychological; Male; Mice; Pyrimidines; Pyrroles; Receptors, Adrenergic, beta-2; Receptors, Corticotropin-Releasing Hormone; Recurrence; Reward; Self Administration; Septal Nuclei; Stress, Psychological | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
Pemphigus erythematosus relapse associated with atorvastatin intake.
Topics: Atorvastatin; Heptanoic Acids; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Pemphigus; Pyrroles; Recurrence | 2014 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
[A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Duodenal Neoplasms; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Middle Aged; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sunitinib; Treatment Outcome | 2014 |
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Polycythemia Vera; Pyrroles; Recurrence; Stroke; Treatment Outcome | 2015 |
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Models, Molecular; Molecular Conformation; Mutation; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Recurrence; Structure-Activity Relationship | 2015 |
Fixed drug eruption due to atorvastatin.
Topics: Aged, 80 and over; Atorvastatin; Drug Eruptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Patch Tests; Predictive Value of Tests; Pyrroles; Recurrence; Risk Factors | 2015 |
[Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2015 |
New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Appendectomy; Azathioprine; Colitis, Ulcerative; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Fecal Microbiota Transplantation; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Leukapheresis; Mercaptopurine; Mesalamine; Methotrexate; New Zealand; Pediatrics; Piperidines; Proctocolectomy, Restorative; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; Tacrolimus; Tumor Necrosis Factor-alpha | 2015 |
Tofacitinib for polyarteritis nodosa: a tailored therapy.
Topics: Adult; Biopsy, Needle; Computed Tomography Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Male; Molecular Targeted Therapy; Piperidines; Polyarteritis Nodosa; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; STAT3 Transcription Factor; Time Factors; Treatment Outcome | 2016 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Treatment Outcome | 2008 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary Body; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Light Coagulation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Ophthalmic Artery; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Stroke; Ultrasonography | 2008 |
[Pubalgia in athlete treated by atorvastatin].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; France; Heptanoic Acids; Humans; Male; Muscular Diseases; Pelvic Pain; Prednisone; Pyrroles; Recurrence; Sports | 2009 |
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2010 |
[An image of vena cava thrombosis].
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Angiogenesis Inhibitors; Fibrinolytic Agents; Heart Atria; Heparin, Low-Molecular-Weight; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Nephrectomy; Postoperative Complications; Pyrroles; Recurrence; Sunitinib; Thrombectomy; Tinzaparin; Tomography, X-Ray Computed; Vena Cava, Inferior; Venous Thrombosis | 2009 |
[Case of branch atheromatous disease presenting capsular warning syndrome].
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atorvastatin; Dextrans; Diffusion Magnetic Resonance Imaging; Drug Therapy, Combination; Heptanoic Acids; Humans; Infusions, Intravenous; Ischemic Attack, Transient; Magnetic Resonance Angiography; Male; Middle Aged; Pyrroles; Recurrence; Syndrome; Thrombolytic Therapy; Tissue Plasminogen Activator | 2010 |
Atorvastatin therapy is associated with improvement of oxidized low-density lipoprotein cholesterol levels, which correlates with the degree of stenosis in patients with carotid atheromatosis with and without prior angioplasty.
Topics: Aged; Aged, 80 and over; Angioplasty; Atorvastatin; Biomarkers; Carotid Stenosis; Cross-Sectional Studies; Down-Regulation; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipoproteins, LDL; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Recurrence; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Color; Ultrasonography, Doppler, Pulsed | 2010 |
Recurrent scrotal hemangiomas during treatment with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Genital Neoplasms, Male; Hemangioma; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Recurrence; Scrotum; Skin Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male physicians.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Risk Reduction Behavior; Stroke; Time Factors; Treatment Outcome | 2011 |
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin | 2011 |
A case of recurrent ventricular tachycardia.
Topics: Aged; Atorvastatin; Cardiovascular Agents; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heptanoic Acids; Humans; Isosorbide Dinitrate; Lisinopril; Nitroglycerin; Pyrroles; Recurrence; Tachycardia, Ventricular; Warfarin | 2011 |
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cetuximab; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Indoles; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recurrence; Sunitinib | 2011 |
[Twenty-one-year survival case of rectal GIST treated with combined therapies].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Pyrroles; Rectal Neoplasms; Recurrence; Sunitinib; Time Factors | 2011 |
Sunitinib reduces recurrent pelvic adhesions in a rabbit model.
Topics: Animals; Disease Models, Animal; Female; Indoles; Postoperative Complications; Protein Kinase Inhibitors; Pyrroles; Rabbits; Recurrence; Sunitinib; Tissue Adhesions; Uterus | 2012 |
Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Recurrence; Sunitinib | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Registries; Retrospective Studies; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
[A case of drug resistant recurrent gastrointestinal stromal tumor treated surgically by resection, partial hepatectomy and diaphragmectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Diaphragm; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Jejunal Neoplasms; Liver Neoplasms; Male; Peritoneal Neoplasms; Piperazines; Pyrimidines; Pyrroles; Recurrence; Sunitinib | 2012 |
[Stable angina pectoris. PTCA improves symptoms, but not prognosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Combined Modality Therapy; Heptanoic Acids; Humans; Hypercholesterolemia; Prognosis; Pyrroles; Recurrence; Risk Factors; Stents; Treatment Outcome | 2002 |
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.
Topics: Animals; Apoptosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Division; Cell Line; Encephalomyelitis, Autoimmune, Experimental; Female; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Mice; Mice, Inbred Strains; Myelin Proteolipid Protein; Paralysis; Peptide Fragments; Pyrroles; Recurrence; Spinal Cord; Th1 Cells | 2003 |
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Topics: Adult; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Blotting, Western; Cell Division; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Eosinophils; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Indoles; Male; Mice; Models, Chemical; Models, Genetic; Molecular Sequence Data; Peptides; Phthalazines; Piperazines; Precipitin Tests; Protein Structure, Tertiary; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Recurrence; Tyrosine | 2003 |
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Topics: Animals; Dog Diseases; Dogs; Enzyme Inhibitors; Indoles; Mast Cells; Mast-Cell Sarcoma; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyrroles; Recurrence | 2003 |
Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect?
Topics: Acute Disease; Aged; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatitis; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides | 2004 |
Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line.
Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Necrosis; Pyrroles; Recurrence; Remission Induction; Transplantation, Heterologous | 2005 |
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Cost Savings; Cost-Benefit Analysis; Diagnosis-Related Groups; Double-Blind Method; Economics, Pharmaceutical; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Spain; Syndrome; Time Factors; Treatment Outcome | 2004 |
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Glomerulonephritis; Glomerulonephritis, Membranoproliferative; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Neuromuscular Diseases; Peritoneal Dialysis; Physical Exertion; Postoperative Complications; Pyrroles; Recurrence; Renal Dialysis; Restless Legs Syndrome | 2005 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |
[After TIA and stroke: a statin for secondary prevention?].
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Placebos; Pyrroles; Recurrence; Stroke; Time Factors | 2006 |
[Musculoskeletal adverse effects of levofloxacin].
Topics: Anti-Bacterial Agents; Arthralgia; Arthritis; Arthritis, Infectious; Arthroplasty, Replacement, Knee; Atorvastatin; Combined Modality Therapy; Debridement; Diagnosis, Differential; Doxycycline; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Levofloxacin; Middle Aged; Ofloxacin; Postoperative Complications; Prosthesis-Related Infections; Pyrroles; Recurrence; Reoperation; Rifampin; Thyroiditis, Autoimmune; Thyroxine; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Recurrence; Risk Factors; Stroke | 2007 |
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke | 2008 |
Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K+c channels.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dogs; Enzyme Activation; Glyburide; Heart; Hemodynamics; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Niacinamide; Nicorandil; Potassium Channels; Pyrroles; Recurrence | 1996 |
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome | 1998 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Recurrence | 1999 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima | 2000 |
Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Topics: Angiogenesis Inhibitors; Antibodies; Ascites; Cell Division; Cells, Cultured; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Humans; Indoles; Lymphokines; Pleural Effusion; Pleural Effusion, Malignant; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Recurrence; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Clinical trials, referral resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Indoles; Platinum Compounds; Pyrroles; Recurrence | 2000 |
The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats.
Topics: Adrenalectomy; Alcoholism; Animals; Corticosterone; Corticotropin-Releasing Hormone; Electroshock; Extinction, Psychological; Injections, Intraventricular; Male; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Recurrence; Self Administration; Stress, Psychological | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
High urinary excretion of N-(pyrrole-2-carboxyl) glycine in type II hyperprolinemia.
Topics: Amino Acid Metabolism, Inborn Errors; Consanguinity; Electroencephalography; Glycine; Growth Disorders; Humans; Infant; Male; Proline; Pyrroles; Recurrence; Seizures | 1990 |
Recurrence and specificity of nephrotic syndrome due to tolmetin.
Topics: Female; Humans; Middle Aged; Nephrotic Syndrome; Pyrroles; Recurrence; Tolmetin | 1989 |